The U.S. Food and Drug Administration (FDA) has issued a Warning Letter to Glenmark Pharmaceuticals Limited. The document dated November 22, 2022 goes back to an inspection from May 12, 2022 to May 20, 2022 at the company's drug manufacturing facility in Goa, India.